Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis

Inflammatory Bowel Diseases

Volumn 16, Issue 12, 2010, Pages 2022-2033

  Yoshino, Takuya ^a   Nakase, Hiroshi ^a   Honzawa, Yusuke ^a   Matsumura, Kayoko ^a   Yamamoto, Shuuji ^a   Takeda, Yasuhiro ^a   Ueno, Satoru ^a   Uza, Norimitsu ^a   Masuda, Satohiro ^b   Inui, Kenichi ^b   Chiba, Tsutomu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

apoptosis; inflammatory bowel disease; macrophage; MAPK; NF B; tacrolimus

Indexed keywords

CASPASE; CASPASE 3; CASPASE 9; DEXTRAN SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; COLITIS; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TACROLIMUS;

EID: 78649549658     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21318     Document Type: Article

References (43)

1. Calkins BM, Mendeloff AI,. Epidemiology of inflammatory bowel disease. Epidemiol Rev. 1986; 8: 60-91.
2. Timmer A,. Environmental influences on inflammatory bowel disease manifestations. Lessons from epidemiology. Dig Dis. 2003; 21: 91-104.
3. Sandborn WJ,. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008; 135: 1442-1447.
4. Sartor RB,. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am. 1995; 24: 475-507.
5. Cario E, Podolsky DK,. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun. 2000; 68: 7010-7017.
6. Kucharzik T, Maaser C, Lugering A, et al. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis. 2006; 12: 1068-1083.
7. Watanabe T, Kitani A, Murray PJ, et al. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol. 2004; 5: 800-808.
8. Massey DC, Parkes M,. Genome-wide association scanning highlights two autophagy genes, ATG16L1 and IRGM, as being significantly associated with Crohn's disease. Autophagy. 2007; 3: 649-651.
9. Henckaerts L, Figueroa C, Vermeire S, et al. The role of genetics in inflammatory bowel disease. Curr Drug Targets. 2008; 9: 361-368.
10. Kaisho T, Akira S,. Toll-like receptors and their signaling mechanism in innate immunity. Acta Odontol Scand. 2001; 59: 124-130.
11. Schenk M, Mueller C,. Adaptations of intestinal macrophages to an antigen-rich environment. Semin Immunol. 2007; 19: 84-93.
12. Kamada N, Hisamatsu T, Okamoto S, et al. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest. 2008; 118: 2269-2280.
13. Nakase H, Okazaki K, Tabata Y, et al. Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J Pharmacol Exp Ther. 2000; 292: 15-21.
14. Kanai T, Uraushihara K, Totsuka T, et al. Ameliorating effect of saporin-conjugated anti-CD11b monoclonal antibody in a murine T-cell-mediated chronic colitis. J Gastroenterol Hepatol. 2006; 21: 1136-1142.
15. Sawada S, Suzuki G, Kawase Y, et al. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol. 1987; 139: 1797-1803.
16. Schreiber SL,. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science. 1991; 251: 283-287.
17. Liu J, Farmer JD, Jr., Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991; 66: 807-815.
18. Schreiber SL, Crabtree GR,. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992; 13: 136-142.
19. Todo S, Fung JJ, Starzl TE, et al. Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg. 1990; 212: 295-305; discussion 306-297.
20. Baumgart DC, Pintoffl JP, Sturm A, et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease-a long-term follow-up. Am J Gastroenterol. 2006; 101: 1048-1056.
21. Qualls JE, Kaplan AM, van Rooijen N, et al. Suppression of experimental colitis by intestinal mononuclear phagocytes. J Leukoc Biol. 2006; 80: 802-815.
22. O'Mahony L, Feeney M, O'Halloran S, et al. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther. 2001; 15: 1219-1225.
23. Cooper HS, Murthy SN, Shah RS, et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993; 69: 238-249.
24. Vowinkel T, Kalogeris TJ, Mori M, et al. Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Dig Dis Sci. 2004; 49: 556-564.
25. Kamada N, Hisamatsu T, Okamoto S, et al. Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria. J Immunol. 2005; 175: 6900-6908.
26. Bettelli E, Kuchroo VK,. IL-12- and IL-23-induced T helper cell subsets: birds of the same feather flock together. J Exp Med. 2005; 201: 169-171.
27. Dong C,. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol. 2006; 6: 329-333.
28. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000; 13: 715-725.
29. Yang J, Murphy TL, Ouyang W, et al. Induction of interferon-gamma production in Th1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur J Immunol. 1999; 29: 548-555.
30. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005; 201: 233-240.
31. Hsieh CS, Macatonia SE, Tripp CS, et al. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993; 260: 547-549.
32. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003; 52: 65-70. (Pubitemid 36020767)
33. Lan CC, Yu HS, Wu CS, et al. FK506 inhibits tumour necrosis factor-alpha secretion in human keratinocytes via regulation of nuclear factor-kappaB. Br J Dermatol. 2005; 153: 725-732.
34. Diestel A, Roessler J, Pohl-Schickinger A, et al. Specific p38 inhibition in stimulated endothelial cells: a possible new anti-inflammatory strategy after hypothermia and rewarming. Vascul Pharmacol. 2009; 51: 246-252.
35. Barton GM, Medzhitov R,. Toll-like receptor signaling pathways. Science. 2003; 300: 1524-1525.
36. Neurath MF, Fuss I, Schurmann G, et al. Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann N Y Acad Sci. 1998; 859: 149-159.
37. Zhang JS, Feng WG, Li CL, et al. NF-kappa B regulates the LPS-induced expression of interleukin 12 p40 in murine peritoneal macrophages: roles of PKC, PKA, ERK, p38 MAPK, and proteasome. Cell Immunol. 2000; 204: 38-45.
38. Saklatvala J,. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol. 2004; 4: 372-377.
39. Choi SJ, You HS, Chung SY,. Tacrolimus-induced apoptotic signal transduction pathway. Transplant Proc. 2008; 40: 2734-2736.
40. Hortelano S, Lopez-Collazo E, Bosca L,. Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. Br J Pharmacol. 1999; 126: 1139-1146.
41. Van Antwerp DJ, Martin SJ, Kafri T, et al. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 1996; 274: 787-789.
42. Beg AA, Baltimore D,. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 1996; 274: 782-784.
43. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993; 75: 263-227.